Among the irAEs encountered in ICI-treated patients, a systematic review has documented that all-grades colitis, hypophysitis, and rash were more frequent with anti-CTLA-4 agents, whereas pneumonitis, hypothyroidism, arthralgia, and vitiligo were more common with anti-PD-1 blockades [11]. Here, CTLA4 is linked to vitiligo.